Perya Bhagchandani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Perya Bhagchandani has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Deena Fayyad
Department of Dermatology University of Maryland School of Medicine Baltimore Maryland USA
2 shared publications - Shawn G. Kwatra
Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA
2 shared publications - Yagiz Matthew Akiska
School of Medicine and Health Sciences, The George Washington University, DC, USA
2 shared publications - Davies Gage
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
1 shared publication - Hannah Cornman
Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA
1 shared publication - Isha Gandhi
University of Minnesota Twin Cities Medical School, Minneapolis, MN
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 706-723
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.
- 13 January 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 706-723
Open AccessPathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.
- Open Access
- 18 October 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (1) , 100422
Nanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis
- 18 October 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (1) , 100422
Open AccessNanostring Transcriptomic Analysis Highlights IL-6 Family and TGF-β Pathways in the Pathogenesis of Prurigo Nodularis